首页 > 市场调查报告书 > 製药

非专利药生技仿製药

2030 年欧洲生物仿製药市场预测 - 按疾病适应症、给药途径、药物类别、分销渠道和地区进行区域分析

市场调查报告书

商品编码

1347207

2030 年欧洲生物仿製药市场预测 - 按疾病适应症、给药途径、药物类别、分销渠道和地区进行区域分析

Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication, Route of Administration, Drug Class, Distribution Channel, and Region

出版日期: 2023年08月04日 | 出版商:

The Insight Partners | 英文 205 Pages | 订单完成后即时交付

价格

简介目录图表

欧洲生物仿製药市场预计将从2022年的103.4486亿美元增长到2030年的1151.2591亿美元；预计2022年至2030年復合年增长率为35.1%。

该报告重点介绍了市场的普遍趋势以及推动市场增长的因素。市场增长归因于慢性病患病率的增加和生物仿製药批准量的增加。此外，在预测期内，生物仿製药和临床试验的合作可能会成为市场的一个重要趋势。然而，生物仿製药产品製造的高成本投入和復杂性阻碍了 2022-2030 年预测期内的市场增长。

生物仿製药和临床试验的合作推动欧洲生物仿製药市场

合资企业和其他合作模式将帮助生物仿製药製造商在未来几年保持相对于市场竞争对手的竞争优势。

通过与其他计划研究、推出和销售生物仿製药的公司合作，生物仿製药製造商可以快速开发产品并有效地推出产品，从而克服专利风险并赢得临床医生和患者对产品的信心。通过获得本地和国外的专业知识、开发平台访问以及研究和临床试验资金，可以加快产品开发。

与更大的生物製药製造商合作可以使用现有的生产设施。这种合作可以针对外包活动，例如细胞系开发、生物製品和生物仿製药製造、工艺扩展以及任何所需的技术转让。

合作可以带来长期利益。它们可以使国内未来生物仿製药生产项目的招标变得容易，并提供早期、高效的产品开发和市场渗透。在像欧洲这样的庞大市场中，国家层面的医疗政策和市场动态存在显着差异，通过此类合作获得的当地知识也被证明是无价的。

生物仿製药市场的巨大潜力催生了许多近期备受瞩目的合作。下面举几个例子：

2023 年 6 月，三星生物製剂宣布与辉瑞建立战略合作伙伴关係，以实现辉瑞多产品组合的长期商业化生产。该协议旨在三星生物製品将为辉瑞提供额外的产能，以大规模生产涵盖肿瘤学、炎症和免疫学的多产品生物仿製药组合。

2023 年 5 月，诺华子公司 Sandoz 宣布与 Evotec Biologics 开展生物仿製药合作。该协议涵盖开发和製造多种生物仿製药，旨在快速开发和随后製造多种生物仿製药。在未来 12-18 个月的合作下，Evotec Biologics 工厂的生物仿製药开发将加快。

因此，生物仿製药生产和临床试验製造商的合作将成为预测期内生物仿製药市场的主要趋势。

重磅生物製剂的专利到期提供了利润丰厚的市场机会

生物製品代表了治疗以前无法治癒的疾病的有前途的新疗法，并且在药品市场中变得非常重要。然而，原研生物製品的专利预计将在未来几年到期。

下表列出了最畅销生物製品的预计专利和独占权到期日。

生物製品到期月份和年份

阿瓦斯汀 2022 年 1 月

西拉姆扎 2023 年 5 月

Adcetris 2023 年 8 月

阿布特拉克斯 2024 年 10 月

加济瓦/加济瓦罗 2024 年 11 月

达扎莱克斯 2026 年 5 月

奥克雷乌斯 2027 年 4 月

Emgality 2028 年 9 月

赫姆利布拉 2028 年 2 月

卢梅特里 2028 年 3 月

伊姆芬齐 2028 年 9 月

迈洛塔格 2028 年 4 月

伊姆芬齐 2028 年 9 月

迈洛塔格 2028 年 4 月

西尔万特 2034 年 7 月

资料来源：仿製药和生物仿製药计划 (GaBI) 杂誌

原研生物製品的专利到期和其他知识产权将在未来产生推出新生物仿製药的需求。因此，未来几年该行业市场参与者之间的竞争将加剧。因此，重磅生物製剂的专利到期预计将在预测期内为生物仿製药市场创造利润丰厚的机会。

2022-2030 年，德国在欧洲生物仿製药市场占据最大市场份额。生物仿製药引入了竞争并提高了生物製剂的可承受性，最终提供节省成本和增值服务来支持患者护理和医疗保健社区。医疗保健专业人员可以用高质量的生物製剂治疗更多患者，同时减少支出。例如，在德国，根据 Sandoz 的数据，2022 年推出生物仿製药后，抗 TNF 药物的每日治疗剂量数量增加了 29%（从 17.18 至 2218 万）。

德国已获得付款人、提供者和患者的认可，将生物仿製药作为适当药物使用的一个组成部分。根据公司设定的价格全额报销，包括患者立即获得生物仿製药。由多个采购集团和独立医院连锁机构进行的医院招标结构使得德国製造商之间的竞争得以维持。例如，2018年11月，德国卫生部提出了药品供应安全法案草案。 Gesetz Fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) 法案旨在为德国药剂师自动替代生物仿製药提供法律框架。

由于节省成本的巨大潜力，德国卫生部出台了一项新法律来增加生物仿製药的采用。由于很少有欧盟 (EU) 国家允许药剂师替代生物仿製药，这将代表实践中的重大变化，特别是对德国而言。此外，在德国，2019 年通过的一项法律预计，从2022 年开始，药房将自动替代生物仿製药，前提是联邦联合委员会（健康保险公司和医疗服务提供者自治的最高决策机构）已确定生物仿製药的互换性。所涉及的药物，并且处方医生没有明确排除该药物。因此，随着德国政府越来越多地采用生物仿製药，市场预计将会增长。

欧洲生物仿製药市场上的公司采用了各种有机和无机策略。有机战略主要包括产品发布和产品批准。此外，市场上出现的无机增长策略包括收购、合作和伙伴关係。这些增长战略使市场参与者能够扩大业务并增强其地域影响力，从而促进整体市场的增长。此外，收购和合作战略有助于市场参与者加强其客户群并扩大其产品组合。下面列出了欧洲生物仿製药市场主要参与者的一些重大进展。

国际糖尿病联盟、欧洲药品管理局、疾病预防控制中心、中国临床肿瘤学、国家综合护理网络是在准备欧洲生物仿製药市场报告时提到的一些主要的一手和二手来源。

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.

In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12-18 months.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .

Biologicals Expiry Month & Years

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

Source: Generics and Biosimilars Initiative (GaBI) Journal

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.

International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biosimilars market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global Europe biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Europe Biosimilars Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Biosimilars Market - Market Landscape

4.1 Overview
- 4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
- 4.2.1 France
- 4.2.2 Germany
- 4.2.3 Italy
- 4.2.4 Spain
- 4.2.5 UK

5. Europe Biosimilars Market

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
- 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
- 5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
- 5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis

6. Europe Biosimilars Market - Regional Analysis

6.1 Europe Biosimilars Market Revenue Forecast and Analysis

7. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Disease Indication

7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
- 7.4.1 Overview
- 7.4.2 Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
- 7.5.1 Overview
- 7.5.2 Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.3 Psoriasis
  - 7.5.3.1 Overview
- 7.5.4 Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.5 Arthritis
  - 7.5.5.1 Overview
- 7.5.6 Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.7 Others
  - 7.5.7.1 Overview
  - 7.5.7.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
- 7.6.1 Overview
- 7.6.2 Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration

8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
- 8.3.1 Overview
- 8.3.2 Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
- 8.4.1 Overview
- 8.4.2 Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Drug Class

9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
- 9.3.1 Overview
- 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
- 9.4.1 Overview
- 9.4.2 Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
- 9.5.1 Overview
- 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Distribution Channel

10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
- 10.3.1 Overview
10.4 Immunologists
- 10.4.1 Overview
10.5 Rheumatologists
- 10.5.1 Overview
10.6 Oncologists
- 10.6.1 Overview
10.7 Dermatologists
- 10.7.1 Overview
10.8 Retina Compounding
- 10.8.1 Overview
10.9 Others
- 10.9.1 Overview
10.10 Hospital Pharmacies
- 10.10.1 Overview
- 10.10.2 Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.3 Endocrinologists
  - 10.10.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.4 Immunologists
  - 10.10.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.5 Rheumatologists
  - 10.10.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.6 Oncologists
  - 10.10.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.7 Dermatologists
  - 10.10.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.8 Retina Specialists
  - 10.10.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.9 Others
  - 10.10.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
- 10.11.1 Overview
- 10.11.2 Compounding Pharmacies : Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.3 Endocrinologists
  - 10.11.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.4 Immunologists
  - 10.11.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.5 Rheumatologists
  - 10.11.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.6 Oncologists
  - 10.11.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.7 Dermatologists
  - 10.11.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.8 Retina Specialists
  - 10.11.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.9 Others
  - 10.11.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
- 10.12.1 Overview
- 10.12.2 Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.3 Endocrinologists
  - 10.12.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.4 Immunologists
  - 10.12.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.5 Rheumatologists
  - 10.12.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.6 Oncologists
  - 10.12.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.7 Dermatologists
  - 10.12.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.8 Retina Specialists
  - 10.12.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.9 Others
  - 10.12.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
- 10.13.1 Overview
- 10.13.2 Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.3 Endocrinologists
  - 10.13.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.4 Immunologists
  - 10.13.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.5 Rheumatologists
  - 10.13.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.6 Oncologists
  - 10.13.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.7 Dermatologists
  - 10.13.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.8 Retina Specialists
  - 10.13.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.9 Others
  - 10.13.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Biosimilars Market - Revenue and Forecast to 2030 - Geographic Analysis

11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
  - 11.1.2.1 Europe Biosimilars Market, by Disease Indication
  - 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
  - 11.1.2.3 Europe Biosimilars Market, by Route of Administration
  - 11.1.2.4 Europe Biosimilars Market, by Drug Class
  - 11.1.2.5 Europe Biosimilars Market, by Distribution Channel
  - 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
  - 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
  - 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
  - 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
  - 11.1.2.10 Europe Biosimilars Market by Country
    - 11.1.2.10.1 Germany
    - 11.1.2.10.1.1 Overview
    - 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
    - 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
    - 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
    - 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
    - 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.2 UK
    - 11.1.2.10.3 Overview
    - 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
    - 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
    - 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
    - 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
    - 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.4 France
    - 11.1.2.10.4.1 Overview
    - 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
    - 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
    - 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
    - 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
    - 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.5 Italy
    - 11.1.2.10.5.1 Overview
    - 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
    - 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
    - 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
    - 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
    - 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.6 Spain
    - 11.1.2.10.6.1 Overview
    - 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
    - 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
    - 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
    - 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
    - 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.7 Rest of Europe
    - 11.1.2.10.7.1 Overview
    - 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
    - 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
    - 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
    - 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
    - 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies

12. Pre and Post COVID-19 Impact

12.1 Pre and Post COVID-19 Impact

13. Biosimilars Market - Industry Landscape

13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
14.4 Biocon Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Eli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Comparison Between Different Drug Developments
Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 66. Recent Organic Growth Strategies in Biosimilars Market
Table 67. Glossary of Terms

List Of Figures

Figure 1. Biosimilars Market Segmentation
Figure 2. Biosimilars Market, by Region
Figure 3. Key Insights
Figure 4. Europe: PEST Analysis
Figure 5. Europe Biosimilars Market- Key Industry Dynamics
Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
Figure 7. Europe Biosimilars Market - Revenue Forecast and Analysis - 2020-2030
Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
Figure 9. Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
Figure 17. Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 26. Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. Compounding Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 35. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 36. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 38. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 39. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 40. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 41. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 42. Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 43. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 44. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 45. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 46. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 47. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 48. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 49. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 50. Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 52. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 53. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 54. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 55. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 56. Retina Compounding: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 57. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
Figure 68. Growth Strategies in Biosimilars Market